Shares in Genmab A/S slid more than 20 percent Monday on news that zalutumumab, an antibody-targeting epidermal growth factor receptor (EGFR), failed to reach the primary endpoint of a pivotal Phase III trial in head and neck cancer. (BioWorld Today) Read More
